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Abstract
Background: There is no consensus on which lung-protective strategies should be used in cardiac surgery patients.
Sparse and small randomized clinical and animal trials suggest that maintaining mechanical ventilation during
cardiopulmonary bypass is protective on the lungs. Unfortunately, such evidence is weak as it comes from surrogate
and minor clinical endpoints mainly limited to elective coronary surgery. According to the available data in the
academic literature, an unquestionable standardized strategy of lung protection during cardiopulmonary bypass
cannot be recommended. The purpose of the CPBVENT study is to investigate the effectiveness of different strategies
of mechanical ventilation during cardiopulmonary bypass on postoperative pulmonary function and complications.
Methods/design: The CPBVENT study is a single-blind, multicenter, randomized controlled trial. We are going to enroll
870 patients undergoing elective cardiac surgery with planned use of cardiopulmonary bypass. Patients will be
randomized into three groups: (1) no mechanical ventilation during cardiopulmonary bypass, (2) continuous positive
airway pressure of 5 cmH2O during cardiopulmonary bypass, (3) respiratory rate of 5 acts/min with a tidal volume of 2–
3 ml/Kg of ideal body weight and positive end-expiratory pressure of 3–5 cmH2O during cardiopulmonary bypass. The
primary endpoint will be the incidence of a PaO2/FiO2 ratio <200 until the time of discharge from the intensive care
unit. The secondary endpoints will be the incidence of postoperative pulmonary complications and 30-day mortality.
Patients will be followed-up for 12 months after the date of randomization.
Discussion: The CPBVENT trial will establish whether, and how, different ventilator strategies during cardiopulmonary
bypass will have an impact on postoperative pulmonary complications and outcomes of patients undergoing cardiac
surgery.
Trial registration: ClinicalTrials.gov, ID: NCT02090205. Registered on 8 March 2014.
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Background
Respiratory failure (RF) is a common complication in car-
diac surgery, with a global incidence of 20–25%. Its clin-
ical manifestation ranges from a mild form of respiratory
failure up to an acute respiratory distress syndrome
(ARDS) requiring prolonged mechanical ventilation (MV)
and intensive care unit (ICU) stay [1].
The pathophysiological mechanism of RF is quite com-
plex, but it is known that cardiopulmonary bypass (CPB)
plays a major role in determining lung injury [2]. A num-
ber of factors contribute to this injury: atelectasis, hyper-
oxygenation causing the release of free radicals [3] and a
CPB-related systemic inflammatory response [4, 5].
It is a common practice to suspend ventilation during
CPB, since lung function is carried out by an extracor-
poreal gas exchanger. However, the interruption of MV
during CPB is associated with the development of
micro-atelectasis, hydrostatic pulmonary edema, reduced
lung compliance and surfactant diffusion.
A recent observational study [5] has identified the dur-
ation of CPB as an important risk factor for the develop-
ment of microbiologically documented pneumonia.
Over recent years, several preventive lung-protective
strategies have been investigated and proposed [6, 7]: ultra-
filtration to remove neutrophils [8], controlled hemodilu-
tion (with a hematocrit higher than 23%), steroids [9] and
adjusting MV settings during CPB, such as the application
of positive end-expiratory pressure (PEEP) or continuous
positive airway pressure (CPAP) of 5–15 cmH2O, low tidal-
high frequency ventilation (100 acts/min), the application
of 100% oxygen inspired fraction (FiO2), and bilateral CPB
which involves using the lungs for blood oxygenation [10].
A recent meta-analysis [11] based on 16 clinical trials
found an increase in oxygenation and a reduction in shunt
fraction [11, 12] immediately after weaning from CPB if
CPAP was applied during CPB. Similar results were ob-
tained with a lung recruitment maneuver (RM) [13] at the
end of CPB. Furthermore, maintaining MV during the en-
tire duration of extracorporeal circulation would reduce
the CPB-related inflammatory response and resultant tis-
sue damage [14–16]. Unfortunately, although adequately
planned, studies are not powered enough to recommend
maintaining MV during CPB as an evidence-based strat-
egy to prevent respiratory complications because major
indicators of clinical outcome (i.e., duration of postopera-
tive MV, length of ICU and hospital stay, and long-term
follow-up) have not been investigated [17–19]. Therefore,
according to the available data in the academic literature,
an unquestionable standardized strategy of lung protec-
tion during CPB cannot be recommended [20–24].
Objectives
We designed a randomized controlled trial to investigate
the effects of three different ventilator strategies in the
short, medium and long term. We are testing the hypoth-
esis that MV during CPB would reduce the incidence of
RF, defined as an arterial oxygen tension (PaO2) and in-
spiratory oxygen fraction (FiO2) ratio (PaO2/FiO2) <200,
and other postoperative pulmonary complications (PPCs).
We identified the PaO2/FiO2 ratio as a summarizing
parameter, even if it is still imprecise and unspecific, be-
cause many different conditions leading to respiratory
insufficiency and hypoxemia can be assessed as a PaO2/
FiO2 ratio modification. We chose it because we were
looking for an objective value that can be easily calcu-
lated by any trained health care operator and that is not
affected by the physician’s judgment. A decreased lung
compliance, increased alveolo-arterial oxygen difference
and increased intrapulmonary shunt fraction may all
lead to a decreased (PaO2/FiO2) ratio. [25, 26]
Methods/design
Trial design
The CPBVENT study is a nonpharmacological, multicen-
ter, single-blind, randomized controlled trial. Protocol
structure was written in compliance to the Consolidated
Standards of Reporting Trials (CONSORT) 2010 State-
ment guidelines and follows the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
Statement). The SPIRIT checklist of this trial can be found
in Additional file 1. The SPIRIT figure of this trial is illus-
trated in Fig. 1.
The study has been registered at ClinicalTrials.gov
with the registration number NCT02090205 and was en-
dorsed by the Study Group on Cardiothoracic and Vas-
cular Anesthesia of the Italian Society of Anesthesia and
Intensive Care Medicine (SIAARTI).
Participants
After Ethics Committee approval, on 2 October 2014
(Approval number 69/INT/2014), we intend to enroll pa-
tients aged 18 years or over who are undergoing elective car-
diac surgery with planned use of CPB, aortic cross-clamping,
median sternotomy and two-lung ventilation. All patients
will provide written informed consent before their inclusion
in the trial. The inclusion and exclusion criteria are shown in
Table 1 (LAS VEGAS study: NCT01601223, [27]).
Endpoints
The primary endpoint will be the incidence reduction
of PaO2/FiO2 ratio <200 until discharge from the
ICU [28, 29].
The secondary endpoints will be the evaluation of the
following:
 Readmission to the ICU for RF
 The global incidence of PPCs after cardiac surgery
(see Table 2 for complete definition)
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 Need for re-intubation
 Need for noninvasive ventilation
 Duration of mechanical ventilation
 Length of the ICU and hospital stay
 Cardiovascular complications
 Short-term and long-term mortality
 Postoperative infections
 Postoperative residual curarization (PORC):
measured with a Train of Four (TOF) and defined as
a “need for pharmacological reversal”
Fig. 1 The SPIRIT figure of this trial
Table 1 Inclusion/exclusion criteria
Eligibility criteria
Inclusion criteria
• Age ≥18 years
• Ability to provide informed consent
• Elective cardiac surgery
• Surgical intervention performed with CPB, aortic
cross-clamping and cardioplegic arrest
• Valvular surgery, coronary surgery, surgery on the
ascending aorta, combined cardiac surgery
• Median sternotomy and bi-pulmonary ventilation
Exclusion criteria
• Patient’s refusal
• Nonelective cardiac surgery
• Previous cardiac surgery
• Anticipated circulatory arrest, aortic endoprothesis, TAVI, Mitraclip
• Thoracotomic approach, with one lung ventilation
• Patients with BMI >30 [24]
• Patients with end-stage chronic kidney disease
(defined as need for dialysis)
• Patients with known respiratory diseases
(ongoing respiratory infections, asthma, COPD, OSAS)
• Patients already intubated before arrival in operating theatre
• Pneumonia in the previous 30 days
• Previous pulmonary resection
• Patients with a preoperative oxygen saturation <90%, or PaO2
< 60 mmHg without supplemental oxygen, or a PaO2/FiO2 ratio
<300, or PaCO2 > 45 mmHg
• Patients with hepatic disease, defined as elevated liver enzymes
(higher than two reference intervals)
• Patients with pulmonary hypertension (defined as preoperative
estimated systolic pulmonary artery pressure >45 mmHg)
BMI Body Mass Index, CPB cardiopulmonary bypass, COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 s, FiO2 fraction of inspired
oxygen, HF high-frequency, OSAS obstructive sleep apnea syndrome, PaCO2 arterial partial carbon dioxide pressure, PaO2 arterial partial oxygen pressure, TAVI
transcatheter aortic valve implantation
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Interventions (randomization and treatment protocol)
The randomization list was created by the coordinating
center with a dedicated software and stratified per cen-
ter, in a 1:1:1 ratio, in blocks of 30. Once the patient
has provided informed consent, the investigator logs
into a dedicated on-line portal to obtain the allocation
arm. From that moment it will be impossible to re-
move the patient’s record card from the online plat-
form and, in any case, the patient will be analyzed
according to the intention-to-treat principle. Any devi-
ation from the ventilation protocol, together with rea-
son for deviation, will be recorded on the Case Report
Form (CRF). All patients will be kept blind to the
allocation.
Patients will be randomly assigned to receive one of
the following ventilator strategies [20] (Fig. 2):
 First arm. No mechanical ventilation during CPB:
patient will be disconnected from the respiratory
circuit
 Second arm. Patients will receive CPAP with PEEP of
5 mmH2O and FiO2 < 80%. To perform CPAP the
ventilator will be set in manual/spontaneous mode,
with a flow of 1–2 L/min and the adjustable pressure
valve (APL) set at 5 cmH2O. The actual pressure will
be checked with a pressure gauge integrated in the
ventilator and a pressure gauge connected to the
proximal end of the endotracheal tube
 Third arm. Patients will be ventilated with a
respiratory rate of 5 acts/min, with tidal volume
(TV) of 2–3 mL/Kg of ideal body weight (IBW) and
PEEP of 3–5 cmH2O
Before and after CPB patients will receive a lung-
protective ventilator strategy [23, 30–32], with a
volume-controlled continuous mandatory ventilation
(VC-CMV) mode along with the following parameters
[20] (Fig. 2):
 Tidal volume (TV) = 6–8 ml/Kg of IBW [22]
 PEEP = 5 cmH2O
 FiO2 < 80%
 I:E = 1:2 (inspiration:expiration ratio)
During CPB our goal will be to maintain PaO2 be-
tween 200 and 250 mmHg in order to avoid hyperoxia-
induced lung injury [3, 33]; moreover, the hematocrit
will be maintained above 24% [34]. During weaning from
CPB we will perform a single alveolar RM. This RM will
be performed manually by the anesthesiologist with a
gas mixture of oxygen and air (with an inspired oxygen
fraction lower than 80%), keeping an airway pressure of
40 cmH2O for at least 7 s [35]. RM duration and any
additional RM in ICU will be recorded. Immediately
after the end of RM, ventilation with PEEP will be re-
sumed. If any additional RM is be performed in the ICU,
Table 2 Definition of postoperative pulmonary complications (PPCs)
Complication Definition
Respiratory insufficiency At least one of the following criteria:
• SpO2 < 90%
• PaO2/FiO2 < 300
• PaCO2 > 45 mmHg
• Dyspnea with respiratory distress or use of accessory muscles
Respiratory infection Evidence of new pulmonary infiltrates on chest radiograph plus at least two of the
following Johanson criteria:
• Body temperature >38 °C or <35.5 °C
• White blood cell count >12,000 mm3 or <4000 mm3
• Purulent sputum
• Presence of a new or evolving infiltrate on chest radiograph within 7 days after
surgery
Pleural effusion Evidence of new hazy opacity of one
hemithorax with preserved vascular shadows on the supine radiograph, or posterior
costophrenic angle blunting on a lateral
chest radiograph, or evidence of a new hypo-anechoic area between visceral and
parietal pleura on chest ultrasonography
Atelectasis Evidence on chest radiography of new parenchymal thickening surrounded by
hyperinflated lung
Aspiration pneumonitis Inhalation of gastric content in the perioperative period with
subsequent acute lung injury
Bronchospasm New expiratory wheezing responsive to treatment with bronchodilators
Pneumothorax Presence of air within the pleural space detected with chest radiograph
or loss of lung sliding of gliding sign on ultrasonographic lung examination
PaO2 arterial partial oxygen pressure, PaCO2 arterial partial carbon dioxide pressure, SpO2 oxygen saturation
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this will be done with the same procedure as in the op-
erating room.
A FiO2 lower than 80% will be set during all periopera-
tive time, since a higher oxygen fraction is widely recog-
nized as harmful [3, 21, 36]. The oxidative stress caused
by hyperoxia could itself be a source of lung damage.
Postoperative ventilation
The anesthesiologist will report in the CRF the mechanical
ventilation setting used during patient transfer from the
operating theatre to the ICU. In the ICU we will apply a
VC-CMV with the same parameters used in the operating
room. Blood oxygen saturation will be constantly moni-
tored with a pulse oximeter. We will report the extubation
time, the duration of mechanical ventilation and the need
for re-intubation. Blood gas analyses will be performed by
the clinician according to clinical needs.
Perioperative management and monitoring
All participating patients, regardless of the study arm into
which they are randomized, will be monitored and managed
following general standard of care practices which aim at
maintaining optimal conditions. Both intraoperative and im-
mediate postoperative anesthetic management (unrelated to
ventilatory management) will be decided by the attending
physician as they see fit, following the established protocols
at each center. Any decision affecting the protocol will be
recorded on the electronic CRF (eCRF).
Intraoperative monitoring will include an electrocar-
diogram (ECG), pulse oximeter, capnography, urine out-
put, invasive blood pressure measurements, advanced
hemodynamic monitoring (pulmonary artery catheter
(PAC)/transesophageal echocardiogram (TEE)), bladder
or esophageal temperature, and Activated Clotting Time
(ACT). Monitoring of anesthetic depth analysis (bispec-
tral analysis, BIS) and neuromuscular blockade (with
TOF) are optional depending on the standard clinical
practice and availability of equipment at each hospital.
The anticoagulant protocol is as follows: heparin
(3 mg/Kg) to achieve an ACT of 200 s for cannula-
tion and 480 s to proceed with the CPB. At the end
of the CPB, protamine (3 mg/Kg) is used (ACT target
<150). In case of allergy to heparin, we will adminis-
ter bivalirudin.
Fig. 2 Ventilation flowchart. Description of the ventilatory strategies used before, during and after cardiopulmonary bypass. Abbreviations: CPB
cardiopulmonary bypass, VC-CMV volume-controlled continuous mandatory ventilation, TV tidal volume, IBW ideal body weight, PEEP positive
end-expiratory pressure, FiO2 inspired oxygen fraction
Bignami et al. Trials  (2017) 18:264 Page 5 of 10
During CPB, mild hypothermia (31–33 °C) and pump
flow of 2.5 L/min/m2 will be applied.
Ventilatory parameters will be monitored by the
anesthesia machine: TV, PEEP, FiO2, peak airway pres-
sure (Paw) and plateau pressure (Pplat).
Data collection and follow-up variables
Investigators will collect all the data on the dedicated
CRF and will insert all the information required in the
online platform. The coordinating center will directly re-
ceive all the information in a very simple data flow, with
safe mechanisms for the protection of personal clinical
information. The website uses an https format and all
patients’ data will be collected anonymously. We have
also implemented regular backups in order to minimize
the risk of data corruption. Only the principal investiga-
tor and the data managers of the coordinating center
will have access to the main database.
Data collection will include: preoperative information
(anamnesis, physical examination, cardiac and pulmon-
ary function, laboratory analysis), intraoperative data
(ventilatory parameters, type of anesthesia, type of cardi-
oplegia, type of CPB circuit, temperature during CPB,
use of volatile anesthetics in CPB, volume and type of
fluids administered, transfusion requirements, use of
vasoactive drugs, duration of intervention, ventilation
mode used during transport to the ICU), postoperative
data (use of inotropic or vasoactive drugs, mechanical
devices, time to extubation, need for respiratory support
or re-intubation and hospital stay). Furthermore, we will
calculate the Euroscore I–II, the ACEF score [37] and
the ARISCAT risk score [38].
After discharge from the hospital, patients will be
phoned for the follow-up. We will record any re-
admission to hospital or exitus. Follow-up will be per-
formed 30 days, 60 days and 1 year after randomization;
we will consider overall mortality.
Statistical considerations
Sample size
Sample-size calculation was based on a two-sided alpha
error of 0.05 and a 80% power (beta). On the basis of re-
spiratory insufficiency incidence after cardiac surgery,
we anticipate that 25% of patients will have a PaO2/FiO2
ratio <200. We expect a reduction of 35% in the inci-
dence of this parameter. We calculate that we will need
a sample size of 263 patients per group, 789 in total. In-
cluding a dropout fraction of 10%, we calculate that we
will need 870 patients to complete the trial.
A significant blind interim analysis (P < 0.0001) will be
performed once half of the patients have been recruited
to assess the recruiting progress and verify that the
hypotheses assumed in the calculation of the sample size
are correct.
Data analysis
We will analyze patients in the treatment group to
which they are allocated. Data will be analyzed with pro-
fessional statistical software. Data will be analyzed ac-
cording to the intention-to-treat principle and following
a pre-established analysis plan. Dichotomous variables
will be compared with the two-tailed Χ2 test, using the
Yates correction when appropriate. Continuous variables
will be compared by analysis of variance or the nonpara-
metric Kruskal-Wallis test, when appropriate. Relative
risks with 95% confidence intervals, and differences be-
tween medians with 95% confidence intervals (using the
Hodges-Lehmann estimation), will be calculated when
appropriate. Two-sided significance tests will be used.
The major comparison will be between the two groups
undergoing MV during CPB and the group with no MV.
Subgroup analyses
We will infer a subgroup effect if the interaction term
of treatment and subgroup is statistically significant at
P < 0.05.
Trial organization
The IRCCS San Raffaele Scientific Institute is the
coordinating center for this study and is primarily re-
sponsible for the organization of the trial, development
of the randomization scheme, study database, data
consistency checks, data analysis and coordination of
the study centers.
As the coordinating center we created an online plat-
form (http://www.cpbvent.it) where investigators can
electronically randomize the patient and load data in the
online CRF. We also assist the other centers with admin-
istrative procedures as well as during the first cases.
All parts of the study will be conducted according to the
Good Clinical Practice (GCP) Statement as well as Italian
and international law on clinical research [39–41].
The trial structure includes the most important Italian
adult cardiac surgical centers with experience of trials
under GCP.
Safety monitoring activities performed by an inde-
pendent monitoring body include reviewing the protocol
with emphasis on data integrity as well as participant
risk and safety issues, monitoring adverse events, and
ensuring that practices are in place to safeguard the con-
fidentiality of the data and results. The monitoring body
must be separate and independent from the clinical staff
or anyone responsible for patient care.
The monitoring body should not have scientific, fi-
nancial or other conflicts of interest related to the
trial. Current or past collaborators or associates of
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the principal investigator should not be a part of the
monitoring body.
Discussion
Postoperative pulmonary complications are frequent
after cardiac surgery. Many factors may contribute to
their development, in particular CPB. Most of these
complications are not severe, but when a severe compli-
cation does occur, a patient’s life may be significantly
threatened. Our effort in this trial is concentrated in par-
ticular on RF (see Table 2) which is still a major cause of
mortality in cardiac surgery.
Pathophysiology of CPB-related lung injury
A possible classification of CPB-mediated lung injury
may follow the anatomical structures involved. Apostola-
kis et al. [42] reviewed the pathological alterations in the
lungs after CPB. Such histological findings may contribute
to hypoxemia, ventilation/perfusion ratio (V/Q) dera-
ngements and atelectasis. In fact, an important hypothesis
regarding post-CPB lung dysfunction is related to an in-
flammatory reaction which has been linked to the use of
the CPB circuit.
Many pathophysiological steps may be involved in
lung injury. Pulmonary atelectasis is but one modifiable
component of pulmonary dysfunction after CPB. Apnea
during CPB has been suggested to promote the activa-
tion of lysosomal enzymes in the pulmonary circulation
which in turn are correlated with the incidence of post-
operative pulmonary dysfunction [43–46]. CPB duration
has also been associated with lung injury and mortality.
Ventilation-associated pneumonia (VAP) also showed a
relation with CPB time and with preoperative pulmonary
conditions [47, 48].
Feasibility and safety of mechanical ventilation during CPB
Many clinical and preclinical trials have demonstrated
the feasibility and safety of MV during CPB and intro-
duced the key question of whether ventilating the pa-
tient’s lungs during CPB can have an impact on
respiratory outcome. However, these are limited to the
perioperative period and do not investigate enough clin-
ically relevant endpoints. Nevertheless, these results
showed the potential effectiveness of mechanical ventila-
tion during CPB to prevent postoperative pulmonary
complications (PPCs). Although it is currently unfeasible
to recommend a unique strategy of lung preservation
during CPB, the growing opinion is that keeping the
lung ventilated, rather than interrupting ventilation dur-
ing CPB, would improve respiratory outcome.
Schreiber et al. [11] analyzed different strategies to
prevent CPB-related lung injury, finding an increase in
oxygenation and a reduction in shunt fraction immedi-
ately after CPB when CPAP was applied during CPB.
The application of low tidal/low frequency ventilation or
vital capacity maneuvers during or after CPB was also
helpful in order to prevent lung injury. Nevertheless,
they found a rather limited impact on postoperative clin-
ical outcomes. However, we find these results with sur-
rogate endpoints [11], encouraging the investigation of
the real clinical impact of ventilation during CPB.
In order to minimize potential biases, we decided to
keep a rigorous scheme of mechanical ventilation for the
patients included in our study. In particular, ventilation
with higher tidal volumes has been associated with worse
respiratory outcome in cardiac surgery [27–29].
Before planning our trial, we reviewed all the random-
ized clinical trials on ventilation during CPB in elective
adult cardiac surgery, published from 2000 to the
present year [11, 49–63]. All randomized trials take into
consideration small-sized samples and limited setting.
Limitations
The CPBVENT trial will enroll patients undergoing
elective cardiac surgery with CPB. Eligible patients usu-
ally have a preserved cardiac function and no significant
risk factors for postoperative respiratory insufficiency
[26, 27]. Our intention is to eliminate the possible selec-
tion biases and build a more homogeneous sample. This
could be a limitation, since the inclusion of higher-risk
patients might be the basis of a higher-powered trial, but
we believe that a “clean” experimental setting would
make it easier to eliminate confounding factors and the
final results will be more extendible to the majority of
our patients. Furthermore, eligible patients will be all
cardiac surgery patients undergoing median sternotomy
and CPB, including patients undergoing mammary ar-
tery bypass graft surgery. We are aware that this could
be a limitation, because ventilation during mammary ar-
tery isolation may make surgery more difficult.
Other possible limitations of our trial could be the
constant PEEP level and short duration of recruitment
maneuvers used. A longer recruitment maneuver could
significantly impair hemodynamic stability because of
the increase in intrathoracic pressure in a delicate phase
of surgery such as weaning from CPB.
We also acknowledge that the primary endpoint ratio
that we chose is very wide and could include many dif-
ferent conditions. A possible alternative endpoint would
have been the incidence of PPCs in the study population.
On the other hand, some false positives might occur if
we consider PPCs after cardiac surgery. For instance,
pneumothorax is much more frequent than in other sur-
gical settings since all patients undergo central venous
catheterization and the surgery involved might include
incision of the pleural surfaces. Moreover, pleural effu-
sion and pulmonary edema might also be consequences
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of depressed cardiac function, with well-functioning
lungs. Moreover, we will collect all data about lung com-
plications after surgery and provide detailed etiologies
for gas exchange problems in our final results.
Furthermore, we acknowledge that the incidence of
25% for a PaO2/FiO2 ratio <200 is high and, even if it is
the one we experienced in our daily practice, the risk of
a final underpowered result is still present. Our choice
was driven by our clinical experience but also by feasibil-
ity. On the other hand, this study is still the largest ever
performed on this topic and we hope to provide some
important insights into CPB-related lung injury patho-
physiology and prevention.
Pulmonary artery perfusion during CPB [63] and pulsatile
pulmonary perfusion [64] have been proposed as a further
approach to attenuate the CPB-related lung dysfunction.
Still, the currently available techniques of pulmonary perfu-
sion during CPB are still emerging and their feasibility is
strongly linked to the surgeon’s experience.
Finally, we are aware that the results obtained from a
specific subgroup of patients, with strict inclusion criteria,
may not be generalizable to the whole population. How-
ever, since this is the first large trial ever performed on this
topic, we decided to create a clean experimental setting.
Further research will be necessary to assess whether our
findings are extendible to other subgroups and to the gen-
eral population of patients undergoing to cardiac surgery
with CPB.
Current trial status
Approval of the final protocol by the local committee at
each center was obtained before starting recruitment.
Patient recruitment at the coordinating center began in
November 2014. As of 21 April 2017, 559 patients have
been recruited into the CPBVENT trial. We plan to in-
volve at least 20 of the most important Italian cardiac
surgery centers. We expect to complete recruitment by
June 2018 with results on the 1-year outcomes being
available in 2019. The final results will be published as
soon as the analysis has been completed.
In conclusion, after closing the present trial we hope
to be able to recommend (or not) an easy and safe,
evidence-based, lung-preservation strategy during CPB
to all patients undergoing cardiac surgery.
Additional file
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